| 1 | development distribution in greece | | | | | | | 3 | 0.52% |
| 2 | to improve patients’ lives | | | | | | | 3 | 0.52% |
| 3 | product development distribution in | | | | | | | 3 | 0.52% |
| 4 | logo big top left | | | | | | | 3 | 0.52% |
| 5 | our mission is to | | | | | | | 3 | 0.52% |
| 6 | mission is to improve | | | | | | | 3 | 0.52% |
| 7 | is to improve patients’ | | | | | | | 3 | 0.52% |
| 8 | distribution in greece international | | | | | | | 3 | 0.52% |
| 9 | in greece international distribution | | | | | | | 2 | 0.35% |
| 10 | health aspiring innovation inspired | | | | | | | 2 | 0.35% |
| 11 | so that we can | | | | | | | 2 | 0.35% |
| 12 | access to health aspiring | | | | | | | 2 | 0.35% |
| 13 | to health aspiring innovation | | | | | | | 2 | 0.35% |
| 14 | aspiring innovation inspired by | | | | | | | 2 | 0.35% |
| 15 | medicair logo big top | | | | | | | 2 | 0.35% |
| 16 | big top left medicair | | | | | | | 2 | 0.35% |
| 17 | facilitate access to health | | | | | | | 2 | 0.35% |
| 18 | the distribution of our | | | | | | | 2 | 0.35% |
| 19 | food supplements operations partnering | | | | | | | 2 | 0.35% |
| 20 | company products pharmaceuticals medical | | | | | | | 2 | 0.35% |
| 21 | in rd new developments | | | | | | | 2 | 0.35% |
| 22 | operations partnering contract manufacturing | | | | | | | 2 | 0.35% |
| 23 | supplements operations partnering contract | | | | | | | 2 | 0.35% |
| 24 | turnover in rd new | | | | | | | 2 | 0.35% |
| 25 | enable or disable cookies | | | | | | | 2 | 0.35% |
| 26 | devices food supplements operations | | | | | | | 2 | 0.35% |
| 27 | vertical integration eu cgmp | | | | | | | 1 | 0.17% |
| 28 | sprays tablets capsules pmdi | | | | | | | 1 | 0.17% |
| 29 | tablets capsules pmdi semisolids | | | | | | | 1 | 0.17% |
| 30 | flexible and tailor made | | | | | | | 1 | 0.17% |
| 31 | products flexible and tailor | | | | | | | 1 | 0.17% |
| 32 | niche products flexible and | | | | | | | 1 | 0.17% |
| 33 | added niche products flexible | | | | | | | 1 | 0.17% |
| 34 | integration eu cgmp value | | | | | | | 1 | 0.17% |
| 35 | semisolids oral liquids foam | | | | | | | 1 | 0.17% |
| 36 | development vertical integration eu | | | | | | | 1 | 0.17% |
| 37 | sprays unit dose amps | | | | | | | 1 | 0.17% |
| 38 | and development vertical integration | | | | | | | 1 | 0.17% |
| 39 | production and development vertical | | | | | | | 1 | 0.17% |
| 40 | capsules pmdi semisolids oral | | | | | | | 1 | 0.17% |